GSK429286A是ROCK1和ROCK2的选择性抑制剂，IC50值分别为14 nM和63nM[1]。 rho-激酶(ROCK)是AGC(蛋白激酶A、蛋白激酶G和蛋白激酶C)家族的成员，在促进肌动蛋白-肌球蛋白介导的收缩力产生中发挥重要作用[2]。 GSK429286A是一种有效的岩石抑制剂，其活性与已报道的岩石抑制剂Y27632不同。使用GST方法，表明GSK429286A处理(10微米)通过抑制介导该磷酸化过程的ROCK来增加Thr850处的MYPT磷酸化[3]。 在患有自发性高血压的雄性Sprague-Dawley大鼠模型中，口服GSK429286A (30 mg/kg)可显著降低平均动脉压，在治疗近2小时后，最大降幅为50 mmHg。

产品性质：

Cas No.:864082-47-3

别名:N-(6-氟-1H-吲唑-5-基)-2-甲基-6-氧代-4-[4-(三氟甲基)苯基]-1,4,5,6-四氢-3-吡啶甲酰胺

化学名: N-(6-fluoro-1H-indazol-5-yl)-6-methyl-2-oxo-4-[4-(trifluoromethyl)phenyl]-3,4-dihydro-1H-pyridine-5-carboxamide

Canonical SMILES:CC1=C(C(CC(=O)N1)C2=CC=C(C=C2)C(F)(F)F)C(=O)NC3=C(C=C4C(=C3)C=NN4)F

分子式:C21H16F4N4O2

分子量:432.37

溶解度:≥ 21.6mg/mL in DMSO, ≥ 2.73 mg/mL in EtOH with ultrasonic and warming

储存条件:Store at -20°C

注意事项：

为了您的安全和健康，请穿实验服并戴一次性手套操作。

References:

[1].Nichols, R.J., et al., Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J, 2009. 424(1): p. 47-60.

[2].Shi, J., et al., Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment. Cell Death Dis, 2013. 4: p. e483.

[3].Davis, D.A., et al., Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer, 2006. 6: p. 22.

[4]. Goodman, K.B., et al., Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors. J Med Chem, 2007. 50(1): p. 6-9.